Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
Allergy Therapeutics plc
(“Allergy Therapeutics”, “ATL” or the “Group”)
Allergy Therapeutics announces FDAclearanceof IND application for novel peanut allergy vaccine candidate VLP Peanut
- Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022
- Topline data from first-in-humantrial expected in H1 2023
- Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of action of the vaccine candidate
26 January2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the United States Food & Drug Administration (FDA) has cleared the Group’s Investigational New Drug application (IND) for its novel virus-like particle (VLP)-based peanut allergy vaccine candidate (“VLP Peanut”).
The clearance by the FDA of the Group’s IND application paves the way for the initiation of the Phase I PROTECT trial which will be run in the United States. The trial will include multiple cohorts beginning with healthy subjects, followed by peanut allergic patients who will undergo skin prick tests, and then peanut allergic patients who will receive subcutaneous injections. The topline data from the Phase I PROTECT trial in adult patients is expected in H1 2023, earlier than the originally intended data readout of Q4 2023.
The potential of an effective short-course peanut allergy vaccine represents a significant opportunity in the $8 billion worldwide food allergy market1. Peanut allergy is one of the most common types of food allergy and its symptoms can range from mild to severe and life-threatening. In the western world, the prevalence of peanut allergy doubled between 2005 and 2015 and it is becoming apparent in Africa and Asia2. Only about 20% of children diagnosed with peanut allergy outgrow it by the time they reach school age. In the US, peanut allergy was the most common cause of severe and fatal food-induced anaphylactic reactions3.
Previously announced primary and secondary data from the VLP001 trial, an ex-vivo biomarker study which took place at Imperial College London, demonstrated a significant 24-fold reduction in basophil activation and histamine release, and reduced IgE binding capacity to B cells, compared to exposure to the major allergen Ara h2. This strongly suggests a promising safety profile with reduced potency to induce allergic reactions.
Analysis of the data also revealed that VLP Peanut has:
- Reduced capacity to induce proliferation of Th2 cells compared to Ara h2 and whole peanut extract.
- The ability to promote IFN- γ and Th1 cells and selected regulatory B cell subsets.
- Demonstrates downregulation of DC2-associated genes.
These data provide strong confidence in the beneficial immunologic mode of action of VLP Peanut – i.e., confirmation of an effective mechanism to promote class switching from the allergic Th2 pathway to the more tolerogenic Th1 pathway.
Manuel Llobet, CEO of Allergy Therapeutics, stated: “We have achieved a key milestone with the FDA’sclearanceof our IND application and look forward to advancing our innovative peanut allergy vaccine candidate into the clinic.We are now one step closer to bringing to patientsa safe and effective short-course vaccinewith the potential to provide long-term protection and a long-lasting protective immune response. I am excited to see the startof the PROTECT trial later this year.”
About VLP Peanut
VLP Peanut is being developed as a novel VLP-based therapy for the treatment of peanut allergy. This novel immunogenic, protective, and non-reactogenic vaccine candidate is based on immunologically optimised Cucumber Mosaic Virus-derived VLPs (CuMVTT) with the major peanut allergen (Arachis hypogaea) (Ara h2) displayed on its surface. Patents behind the technology to treat peanut allergy with VLP Peanut have been granted in the US and are at the national phase in other territories.
This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.
- ENDS -
1. The Journal of Allergy and Clinical Immunology 2016. 1% of US population. EACCI Food Allergy and Anaphylaxis Guidelines Group 2016 0.2% of Western European Population. Management assumption of annual treatment of $2k
2. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy [published correction appears in N Engl J Med. 2016 Jul 28;375(4):398]. N Engl J Med. 2015;372(9):803‐813.
3. Sampson H, Shreffler W, Yang W, Sussman G, Brown-Whitehorn T, Nadeau K et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity. JAMA. 2017; 318 (18):1798.
For further information, please contact:
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
Stern Investor Relations, Inc.
+1 212 362 1200
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.